Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
tyrosine kinase inhibitor
|
| gptkbp:approves |
gptkb:2012
gptkb:FDA |
| gptkbp:clinical_trial |
approximately 100%
|
| gptkbp:developed_by |
gptkb:Ariad_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ponatinib
|
| gptkbp:ingredients |
C22 H24 Cl N7 O2 S
|
| gptkbp:is_atype_of |
L01 X E30
|
| gptkbp:is_used_for |
gptkb:chronic_myeloid_leukemia
gptkb:healthcare_organization |
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Iclusig
|
| gptkbp:side_effect |
cardiovascular events
thrombosis myelosuppression |
| gptkbp:targets |
gptkb:BCR-ABL_fusion_protein
|
| gptkbp:type_of |
943319-65-1
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
5
|